Treatment of airway mucus hypersecretion.

@article{Rogers2006TreatmentOA,
  title={Treatment of airway mucus hypersecretion.},
  author={Duncan F. Rogers and Peter J Barnes},
  journal={Annals of medicine},
  year={2006},
  volume={38 2},
  pages={
          116-25
        }
}
Airway mucus hypersecretion is now recognized as a key pathophysiological feature in many patients with asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis. Consequently, it is important to develop drugs that inhibit mucus hypersecretion in these susceptible patients. Conventional therapies, including anticholinergics, ss2-adrenoceptor agonists, corticosteroids, mucolytics and macrolide antibiotics, have variable efficacy in inhibiting airway mucus hypersecretion, and are… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 81 CITATIONS, ESTIMATED 55% COVERAGE

Effect of verapamil on bronchial goblet cells of asthma: an experimental study on sensitized animals.

  • Pulmonary pharmacology & therapeutics
  • 2012
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Tussilagone suppressed the production and gene expression of MUC5AC mucin via regulating nuclear factor-kappa B signaling pathway in airway epithelial cells

  • The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology
  • 2018
VIEW 2 EXCERPTS
CITES BACKGROUND

Airway Mucus and Asthma: The Role of MUC5AC and MUC5B

  • Journal of clinical medicine
  • 2017
VIEW 1 EXCERPT
CITES BACKGROUND

FILTER CITATIONS BY YEAR

2006
2019

CITATION STATISTICS

  • 5 Highly Influenced Citations